摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(氯甲基)-1-甲基哌啶 | 52694-50-5

中文名称
3-(氯甲基)-1-甲基哌啶
中文别名
——
英文名称
3-(chloromethyl)-1-methylpiperidine
英文别名
——
3-(氯甲基)-1-甲基哌啶化学式
CAS
52694-50-5
化学式
C7H14ClN
mdl
——
分子量
147.648
InChiKey
FFOIFAAVWJZLFE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    69 °C(Press: 11 Torr)
  • 密度:
    0.984±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933399090

SDS

SDS:a23a1350de8d714b5941825a64869aa6
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrimidin-aminomethyl-pyridine derivatives, their preparation and their use in the control of helicobacter bacteria
    申请人:BYK Gulden Lomberg Chemische Fabrik GmbH
    公开号:US06395732B1
    公开(公告)日:2002-05-28
    The present invention relates to compounds of formula (I) wherein R1, R2, and R3 are hydrogen, 1-4C-alkyl, or halogen; R4, R5, R6, and R9 are hydrogen or 1-4C-alkyl; R7 and R8 are hydrogen, 1-4C-alkyl, 1-4C-alkoxy, or halogen; A is 1-7C-alkylene, 2-7C-alkenylene, 3-7C-cycloalkylene, or phenylene; G is hydrogen, hydroxyl, 1-7C-alkyl, 1-4C-alkyl substituted by fluorine, 2-7C-alkenyl, 3-7C-cycloalkyl, a mono- or di-1-4C-alkylcarbamoyl or -thiocarbamoyl, N-1-4C-alkyl-N′-cyanoamidino, 1-N-1-4C-alkylamino-2-nitroethylene, N-2-propynyl-N′-cyanoamidino, aminosulfonylamidino, —N(R10)R11, the part of the compound of formula (I) bonded to A, glucopyranoside, or a cyclic system or bicyclic system which is optionally substituted by R12 and R13; X is oxygen, N-1-4C-alkyl, NH, or S; Y is oxygen, N-1-4C-alkyl, NH, S, 1,4-piperazinylene, or 1,4-piperidinylene; Z is oxygen, N-1-4C-alkyl, NH, S, or CO; m is from 1 to 7; n is from 0 to 4; t is 0, 1, or 2; and u is 0 or 1, and their salts suitable for controlling Helicobacter bacteria.
    本发明涉及式(I)的化合物,其中R1、R2和R3为氢、1-4C-烷基或卤素;R4、R5、R6和R9为氢或1-4C-烷基;R7和R8为氢、1-4C-烷基、1-4C-烷氧基或卤素;A为1-7C-烷基、2-7C-烯基、3-7C-环烷基或苯基;G为氢、羟基、1-7C-烷基、受氟取代的1-4C-烷基、2-7C-烯基、3-7C-环烷基、一或二个1-4C-烷基氨基甲酰基或硫代氨基甲酰基、N-1-4C-烷基-N′-氰基氨基甲酰基、1-N-1-4C-烷基氨基-2-硝基乙烯、N-2-丙炔基-N′-氰基氨基甲酰基、氨基磺酰氨基甲酰基、—N(R10)R11,与A结合的式(I)化合物的部分、葡萄糖吡喃苷或可选择由R12和R13取代的环状系统或双环系统;X为氧、N-1-4C-烷基、NH或S;Y为氧、N-1-4C-烷基、NH、S、1,4-哌嗪亚烷基或1,4-哌啶亚烷基;Z为氧、N-1-4C-烷基、NH、S或CO;m为1至7;n为0至4;t为0、1或2;u为0或1,及其适用于控制幽门螺杆菌的盐。
  • [EN] BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS<br/>[FR] COMPOSÉS BIARYLES UTILES EN TANT QU'IMMUNOMODULATEURS
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2018044963A1
    公开(公告)日:2018-03-08
    The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    本公开涉及通常用作免疫调节剂的化合物。本文提供了包含这些化合物的组合物,以及它们的使用方法。该公开进一步涉及包含至少一种根据本公开的化合物的药物组合物,用于治疗各种疾病,包括癌症和传染病。
  • 4-fluorobenzoic compounds with 5-HT.sub.2 - and .alpha..sub.1
    申请人:Adir et Compagnie
    公开号:US05077288A1
    公开(公告)日:1991-12-31
    The invention relates to the compounds of general formula I: ##STR1## in which: m represents an integer from 2 to 4, n and p, which may be identical or different, each represent an integer from 1 to 3, q represents 0 or 1, and R represents: either a group of formula (A): ##STR2## or a radical of formula (B): ##STR3## or a 2,4-dioxo-1,2,3,4-tetrahydroquinazolinyl radical, on condition, however, that, in this case, n and p do not simultaneously represent the number 2, or a benzhydryloxy group, or a 1-oxophthalazinyl radical, or a 5-oxothiazolo[3,2-A]pyrimidinyl radical, or a group of formula C: ##STR4## their possible stereoisomers and their addition salts with a pharmaceutically acceptable inorganic or organic acid. The compounds of formula I are medicinal products with useful 5-HT.sub.2 - and .alpha..sub.1 -antagonistic activities.
    该发明涉及一般式I的化合物:##STR1##其中:m代表2到4之间的整数,n和p可以相同也可以不同,每个代表1到3之间的整数,q代表0或1,R代表:要么是式(A)的基团:##STR2##要么是式(B)的基团:##STR3##或者是2,4-二氧-1,2,3,4-四氢喹唑啉基团,但在这种情况下,n和p不能同时代表数字2,或者是苯甲基氧基团,或者是1-氧基喹唑啉基团,或者是5-氧代噻唑并[3,2-A]嘧啶基团,或者是式C的基团:##STR4##它们的可能立体异构体及其与药学上可接受的无机或有机酸形成的加合盐。式I的化合物是具有有用的5-HT.sub.2-和α.sub.1-拮抗活性的药物产品。
  • [EN] INHIBITORS OF MALT1 PROTEASE<br/>[FR] INHIBITEURS DE LA PROTÉASE MALT1
    申请人:HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH
    公开号:WO2014086478A1
    公开(公告)日:2014-06-12
    The present invention relates to compounds which are inhibitors of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALTl) and to their use in therapy, in particular in the treatment or prevention of a disease or disorder which is treatable by an inhibitor of a paracaspase. The present invention also relates to pharmaceutical compositions containing such compounds.
    本发明涉及作为粘膜相关淋巴组织淋巴瘤易位蛋白1(MALT1)抑制剂的化合物及其在治疗中的应用,尤其是在治疗或预防可通过抑制paracaspase治疗的疾病或失调中的应用。本发明还涉及含有该化合物的药物组合物。
  • Tricyclic compounds
    申请人:SPOFA, spojene podniky pro zdravotnickou vyrobu
    公开号:US04431808A1
    公开(公告)日:1984-02-14
    A technique is described for the preparation of a wide variety of basic derivatives of linearly condensed tricyclic systems formed by two external benzene nuclei and a 7-membered central ring having 2 chalcogen atoms as hetero atoms. Derivatives of 11H-dibenzo(b,e)-1,4-dioxepin are obtained when the chalcogens are both oxygen atoms; derivatives of 11H-dibenzo(b,f)-1,4-dithiepin are obtained when the chalcogens are both sulfur atoms; derivatives of 6H-dibenz(b,e)-1,4-oxathiepin and 11H-dibenz(b,f)-1,4-oxathiepin are obtained with combinations of sulfur and oxygen atoms as chalcogens.
    描述了一种技术,用于制备由两个外部苯核和一个具有2个硫族元素原子作为杂原子的7-成员中心环形成的线性紧凑三环系统的各种基本衍生物。当硫族元素均为氧原子时,得到11H-二苯并(b,e)-1,4-二氧杂环己烷的衍生物;当硫族元素均为硫原子时,得到11H-二苯并(b,f)-1,4-二硫杂环己烷的衍生物;当硫族和氧族元素的组合作为硫族元素时,得到6H-二苯并(b,e)-1,4-氧硫杂环己烷和11H-二苯并(b,f)-1,4-氧硫杂环己烷的衍生物。
查看更多